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We analyzed the tyrosinase (TYR) gene of 12 Korean patients with various types of 
oculocutaneous albinism (OCA). We identified five different mutations in the TYR gene in 
4 patients with severe OCA and in 2 patients with mild OCA, but found no mutations in 
the 6 patients with mild OCA phenotypes. Among the 5 mutations, a frameshift mutation, 
P310insC, was detected most frequently (allele frequency=O.5), and the other mutations 
were found less frequently, two of which, L288delT and IVS2- 7t--->a,- 10--11deltt, are nov-
el. This study may provide valuable information for the molecular diagnosis of and 
accurate genetic counseling for OCA1 in Koreans and perhaps other Asian groups. 
Oculocutaneous albinism (OCA) is a heterogeneous 
group of autosomal recessive disorders of melanin 
pigmentation found in all populations throughout the 
world (Spritz, 1994; Spritz and Hearing, 1994; Wit-
kop et aI. , 1989). The prevalence of OCA in Koreans 
is not known, but OCA occurs with a frequency of 
approximately 1/16,000-20,000 in the United States 
(Witkop et aI. , 1989). OCA is characterized by re-
duced or absent biosynthesis of melanin pigment in 
melanocytes of the skin, hair follicle, and eye. As a 
result, affected individuals typically exhibit reduced 
visual acuity, nystagmus, strabismus, photophobia, 
and extremely fair complexion with a high risk of 
skin cancers due to actinic damage. 
The two principal forms of OCA are OCA1 
(tyrosinase-related OCA) and OCA2 (P-related OCA) 
(Spritz, 1994). OCA1 is associated with deficient ac-
tivity of melanocyte tyrosinase, a copper-containing 
enzyme that catalyzes the rate-limiting step of me-
lanin biosynthesis (Lerner and Fitzpatrick, 1950; Lern-
er et aI., 1949; Tripathi et aI., 1992a). In OCAlA 
(tyrosinase-negative OCA1), complete lack of me-
lanin biosynthesis results from a complete absence of 
tyrosinase activity (Tomita et al. , 1989; Tripathi et ai., 
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1992a). In OCA1B (yellow OCA1), less severe hy-
popigmented phenotypes result from tyrosinase ac-
tivity that is greatly reduced, but not absent (Giebel 
et aI., 1991a). OCA2 is typically less severe than 
OCA1, but it is difficult to distinguish OCA2 from 
OCA1B on clinical grounds (Spritz, 1994; Spritz and 
Hearing, 1994). 
More than 50 different mutant alleles of the tyro-
sinase (TYR) gene have now been identified in pa-
tients with OCA1 (Spritz, 1994; Spritz and Hearing, 
1994). However, only three OCA1 mutations, 
P31OinsC, R77Q, and D383N, have been identified in 
the three Korean patients studied to date (park et aI., 
1996). Here we report analysis of the TYR gene in 12 
Korean patients with OCA. We identified five dif-
ferent pathologic TYR gene mutations in 4 patients 
with severe OCA and in 2 patients with mild OCA, 
but none in any of the 6 patients with mild OCA. 
Materials and Methods 
PCR amplification of the human TYR gene 
Genomic DNA was isolated from peripheral-blood 
leukocytes from patients with OCA, available family 
members, and unrelated normal controls (Sambrook 
et aI. , 1989). The PCR primers specific to the human 
TYR gene were designed to amplify each of the 3 
The abbreviations used are: OCA, oculocutaneous albinism; 
PCR, polymerase chain reaction; SSCP, single-strand con-
formation polymorphism. 
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Table 1. Primer pairs used to amplify 1YR exon segments by PCR 
Exon Primer sequences Nucleotide position " Fragment size (bp) 
1A 5'-TTITCAGAGGATGAAAGCT-3' 496-514 483 
5'-AGTTTCCACAGTTGAA TCCC-3' 978-959 
IB 5'-CITCACAGGGGTGGATGACC-3' 881-900 436 
5'-CAAGAAGAGTCT ATGCCAAG-3' 1316-1297 
lC 5'-TTGCCCATGAAGCACCAGC-3' 1270-1288 293 
5'-TT ATACCCTGCCTGAAGAAG-3' 1562-1543 
2 5'-CCTCAGGAGAAGTCT AACAAC-3' 1643-1663 445 h 
5'-ACAACACATA TTCTTGGTC-3' 2087-2059 
3 5'-TGGGTATCCAGAA TGT AAA-3' 2134-2152 356 
5'-TTTAAATCCAATGAGCACG-3' 2489-2471 
4 5'-ATCTTTCCATGTCTCCAGA-3' 2493-2511 369 
5'-T AAAGTTTTGTGTT ATCTCA-3' 2861-2842 
5 ' 5'-CTCCAAAGGACTGTGAAAGG-3' 2963-2982 415 
5'-GGTCTTT ACAGAAAAA T AC-3' 3377-3359 
"The nucleotide position followed the numbering system of Giebel et al. (1991b). 
bSince all of the Korean patients and normal controls studied here were found to have the allele consisting of 4 thymidines 
at nucleotides 2059-2061, the actual fragment size of exon 2 was 446 bp in the studied samples. 
overlapping regions of large exon 1 with adjacent 
flanking sequences and each of the eXOnS 2-5 plus ad-
jacent flanking sequences ' (Table 1). Each eXOn seg-
ment was amplified from genomic DNA by 35 cycles 
of PCR using Taq DNA polymerase and heating at 94 
°C for 1 min, followed by 35 cycles of reaction at 94 
°C for 40 s, at 52°C for 90 s, and at 72 °C for 2 min, 
and followed by incubation at 72 °c for 5 min (Saiki 
et aI., 1988). 
Identification of point mutations in the TYR gene 
The amplified exon segments were screened for 
point mutations by simultaneous analyses of single-
strand conformation polymorphisms (SSCPs) and het-
eroduplexes (Lee et ai., 1995) using the MDE gel 
(AT Biochem, Malvern, PA, U.S.A.). Exon segments 
that showed aberrant patterns were independently re-
amplified from genomic · DNA in duplicate, cloned 
into pGEM-T (Prom ega, Madison, WI, U.S.A.), and 
the complete nucleotide sequences of at least six in-
dependent clones per re-amplified eXOn segment were 
determined (Sanger et ai., 1977). 
Results 
The five eXOnS of the TYR gene were amplified 
from genomic DNA of the OCA patients, available 
family members, and unrelated normal controls. The 
PCR products were screened for mutations by nOn-ra-
dioactive simultaneous SSCP/heteroduplex analyses 
as previously described (Lee et ai., 1995). Aberrant 
SSCP/heteroduplex band patterns were detected in 6 
of the 12 Korean patients with OCA (Fig. 1). Spe-
cific mutations were determined by DNA sequencing 
of eXOn segments showing aberrant SSCP/hetero-
duplex band patterns. 
Patient 1 was a 31 year old Korean female with 











Figure 1. SSCP and heteroduplex patterns of the 1YR exon 
PCR products from patients with OCA 1 and normal 
controls. Slow-migrating bands and fast-migrating bands 
correspond to single-stranded DNAs and duplex DNAs, 
respectively. Abberrantly migrating SSCP and heteroduplex 
bands are marked with arrowheads. The exon segments 
showing aberrant SSCPlheteroduplex band patterns were 
cloned and sequenced to identify specific mutations. A-E, 
the band patterns of the TYR exon PCR products homo-
zygous for normal alleles (N) and heterozygous for normal 
and mutant alleles (P); R77Q substitution, P310insC frame-
shift, R299H substitution, L288delT frameshift, and IVS2 
- 7t--->a, - 10-- 1l deltt mutation, respectively. 
irides, foveal hypoplasia, nystagmus, and strabismus. 
SSCP/heteroduplex screening and DNA sequence 

















Asp Asp Arg Glu Ser 





Arg Thr Pro Arg Leu 
AGA ACC CCA AGG CTC ... 
! 
CCC AAG ... TGA 
Pro Lys TER 
299 
Leu Arg Arg Asn Pro 





Gin Ser Leu Cys Asn 
CAG TCT ITA TGC AAT . , . 
! 
317 
-TAT GCA '" TAG 
Tyr Ala TER 
318 
I VS2 Exon 3 
Phe 
atttttttttaatgaacag GA TTT .. . 
U ! 
--aaa 
Figure 2. Mutations of the TYR gene found in Korean pa-
tients with OCA1. (A) R77Q substitution found in patient 
l. (B) P310insC frameshift found in patients 1, 2, 3, 5, and 
6. (C) R299H substitution found in patient 2. (D) 
L288deiT frameshift found in patient 4. (E) IVS2- 7t--+a, 
- 10- - lldellt mutation found in patients 5 and 6. The hy-
phen, " - ", shown in D and E, represents a deleted nu-
cleotide. 
analyses demonstrated that she was a compound het-
erozygote for a missense substitution, R77Q (Figs. 
lA and 2A), and a frameshift, P310insC (Figs. 1B 
and 2B). Both of these mutations had previously 
been identified in Japanese patients with OCAlA and 
completely abolish tyrosinase catalytic activity 
(Takeda et al., 1990; Tomita et aI., 1989). In addition, 
we recently found these same two alleles in two ad-
ditional Korean patients with OCAlA (Park et al., 
1996), suggesting that these two OCAlA alleles may 
be relatively common in Asian patients with OCA 
Patient 2 was a 5 year old Korean female with typ-
ical OCAlA, clinically similar to patient 1. SSCP/het-
eroduplex screening and DNA sequence analyses de-
monstrated that she was a compound heterozygote for 
the P310insC frameshift (Fig. 2B) described above 
and for another missense substitution, R299H (Figs. 
1 C and 2C). The R299H substitution has previously 
been found in Caucasian and Arab patients with 
OCAlA (Gershon i-Baruch et aI., 1994; Tripathi et al. , 
1992b), but has not previously been found in Asians. 
Patient 3 was a 3 year old Korean male with typ-
ical OCAlA SSCP/heteroduplex screening and DNA 
sequence analyses demonstrated that he was het-
erozygous for the P310insC frameshift (Fig. 2B). No 
mutation could be identified in the other allele. 
Patient 4 was a 3J2 year old Korean female with 
typical OCAlA SSCP/heteroduplex screening and 
DNA sequence analyses demonstrated that she was 
heterozygous for a novel frameshift, L288delT (Figs. 
1D and 2D), resulting in a truncated and thus most 
likely nonfunctional polypeptide. No mutation could 
be identified in the other allele. 
Patient 5 was a 4 year old male with mild OCA, 
with slight skin and iris pigmentation and yellow-
brown hair. Visual acuity was reduced, but neither 
nystagmus nor strabismus was detected. SSCP/het-
eroduplex screening and DNA sequence analyses de-
monstrated that he was a compound heterozygote for 
the P310insC frameshift (Fig. 2B), and a novel splice 
site junction mutation, IVS2- 7t-->a,-1-- 11deltt (Figs. 
IE and 2E). Since the P310insC frame shift is known 
to be an OCAlA allele (Tomita et aI. , 1989), the 
mild OCA phenotype of this patient is most likely as-
sociated with the IVS2- 7t-->a, - 1-- lldeltt mutation, 
which thus would be an OCAIB allele. 
Patient 6 was a 6 year old Korean male with mild 
OCA, clinically similar to patient 5. SSCP/hetero-
duplex screening and DNA sequence analyses de-
monstrated that he was a compound heterozygote for 
the P310insC and the IVS2- 7t-->a, - 1-- 11deltt mu-
tations described above (Figs. 2B and 2E), exactly as 
in patient 5. 
Patients 7-12 all exhibited clinically mild OCA, 
with phenotypes similar to or milder than that of pa-
tient 5, except that patient 12 additionally sh0wed 
mild mental retardation. SSCP/heteroduplex screening 
of the TYR genes of these patients demonstrated no 
apparent abnormalities. Therefore, these patients most 
likely have OCA2, rather than OCA1E. 
In the course of this study we identified a novel 
silent polymorphism within IVS2, consisting of four 
versus three thymi dines at nucleotides 2059-2061 of 
the published TYR genomic sequence (Giebel et aI., 
1991b). Because all of the tested 37 Korean in-
dividuals were found to have only the allele with 
four thymi dines, it appears that this allele is ex-
tremely predominant in Korean populations. 
Discussion 
OCA is a rare autosomal recessive genetic disorder 
characterized by deficient biosynthesis of melanin pig-
ment in the skin, hair, and eyes. OCA1 results from 
abnormalities of the TYR gene (Spritz, 1994; Tomita 
et aI., 1989), whereas OCA2 results from ab-
normalities of the P gene (Lee et al. , 1994; Rinchik 
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et ai., 1993). Although a large number of mutations 
have been described in the TYR gene in patients with 
OCA1 (Spritz, 1994; Spritz and Hearing, 1994), very 
few Asian patients have been studied previously 
(Park et ai., 1996; Takeda et ai., 1990; Tomita et aZ., 
1989). 
We analyzed the TYR gene in 12 Korean patients 
with OCA In four of these patients, all of whom 
were affected with apparent OCAlA, we identified 4 
different pathologic mutations. Only one of these mu-
tations was novel, a frameshift, L288delT. The 
L288deiT frameshift results in a truncated and most 
likely completely nonfunctional tyrosinase poly-
peptide (Fig. 2D). The P310insC frameshift also 
results in a truncated tyrosinase polypeptide (Fig. 2B) 
and was reported to completely lack the tyrosinase ca-
talytic activity (Tomita et ai. , 1989). The R77Q sub-
stitution was demonstrated to have no detectable tyro-
sinase catalytic activity in transient expression assays 
(Takeda et ai., 1990). These latter two alleles, which 
had been identified only in Japanese patients (Takeda 
et aZ., 1990; Tomita et aZ., 1989), appear to be re-
latively frequent in Korean patients with OCA (Table 
2). This result suggests that these mutant alleles may 
be specific to and prevalent in far-east Asian po-
pulations, although the total number of patients stu-
died to date is still relatively small. The R299H sub-
stitution was first identified in a Caucasian patient 
and subsequently in an Arab patient both with OCAlA 
(Gershoni-Baruch et al., 1994; Tripathi et aZ., 1992b). 
Identification of the R299H substitution in 
patients with OCAlA demonstrates that it completely 
abolishes the tyrosinase catalytic activity . The pre-
sence of the R299H substitution in Korean po-
pulations suggests that it may have been introduced 
into the Korean population from these groups. 
However, there has been no substantial historical con-
tact between Koreans and Caucasians or Arabs, and 
patient 2, in whom the R299H mutation was iden-
tified, has no known non-Korean ancestors. Thus, it 
is possible that the R299H allele may have arisen in-
dependently in Korea. 
Eight of the Korean OCA patients studied here ex-
hibited relatively mild OCA phenotypes, charac-
teristic of either OCA1B or OCA2. Two of these 
patients were heterozygous for the P310insC frame-
shift, which appears to be the most prevalent OCA1 
allele among Korean patients (allele frequency=0.5) 
(Table 2). In these two patients we identified a novel 
splice site junction mutation, IVS2- 7t->a, - 10-- 11 
deJtt, in the other allele. Since the P310insC mutation 
is known to completely abolish tyrosinase catalytic 
activity (Tomita et aZ., 1989), the IVS2- 7t->a, - 10-- 11 
deltt mutation must be an OCA1B allele associated 
with a small amount of enzymatic activity. The 3' 
splice site of the normal IVS2 (Fig. 2E) contains only 
one pyrimidine (the - 7th position of IVS2) among 
the downstream 5 pyrimidine sites of the pyrimidine 
track in the consensus sequence of the 3' splice site, 
yyyyyyyyyyynyagG (Locker, 1992). The IVS2- 7t->a, 
- 10- - l1deltt mutation changes the pyrimidine to a 
purine. We speculate that this change may greatly 
reduce, but not completely destroy, normal splicing 
of the IVS2 and that the mutant allele thus results in 
a residual tyrosinase catalytic activity. Interestingly, a 
very similar mutation, IVS2 - 7t->a (tgaacagGA -> 
agaacagGA), has previously been observed among 
Jewish and Caucasian patients with OCA1B 
(Gershoni-Baruch et ai., 1994; Spritz et aZ., 1997). 
Both of the Korean IVS2- 7t->a, - 10- - l1deltt mu-
tation and the Jewish/Caucasian IVS2- 7t->a mutation 
involve a thymidine to adenosine transversion at the 
- 7th position of IVS2, but the Korean IVS2- 7t->a, 
- 10- - 11deltt mutation additionally involves a dele-
tion of two thymidines at the - 10th and - 11th po-
sitions of IVS2 (Fig. 2E). Because there has been no 
substantial historical contact between Koreans and 
Jewish or Caucasian populations prior to the Korean 
war, the IVS2-7t->a,-10--11deltt mutation may have 
been occurred in Korean populations, independently 
from the Jewish/Caucasian IVS2- 7t->a mutation. Alt-
ernatively, the IVS2- 7t->a OCA mutant allele may 
have been introduced into the Korean population, and 
was subsequently modified by the additional deletion 
of two thymidines. 
In six of the patients with mild OCA we studied, 
we found no abnormalities of the TYR gene. As it is 
difficult or impossible to distinguish OCA1B from 
OCA2 on solely clinical grounds, it seems most like-
ly that these six patients have OCA2. 
Recently , there has been increased awareness of, 
and attention paid to, genetic diseases in Asian coun-
tries . Identification of prevalent and/or novel OCA 
alleles in Korea will greatly facilitate DNA-based 
Table 2. Mutations of the IYR gene identified in Korean patients with OCAI 






IVS2 - 7t-+a, - l0- - lldeltt 
lA 1(2) Japanese 
lA 1 Korean 
lA 1 Caucasian 
lA 5(3) Japanese 
lA 0(1) Caucasian 
lB 2 Korean 
Reference 
Takeda et ai. , 1990 
This study 
Gershoni-Baruch et ai., 1994 
Tomita et al., 1989 
Spritz et al., 1990 
This study 
"The figures represent occurrences of each specific OCA allele in this study. The figures in parentheses represnent 
occureences in three Korean patients with OCAlA in the previous study (Park et al., 1996). 
Vol. 7 (1997) Sang-Kyu Park et al. 191 
diagnosis, prenatal diagnosis, and carrier screening of 
OCA in Korea and perhaps other Asian populations. 
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